retatrutide phase 3 trials Eli Lilly's clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Initial Reta Phase 3 Trials

It is an investigational triple hormone receptor agonist

Because they significantly alter your metabolic rate and digestive speed, their impact on other hormonal systemsespecially the thyroidis a topic of significant clinical interest

Its accepting that they need ongoing treatment

H., Peters, T

Dulaglutide was found to suppress this complex by reducing the expression of NLRP3, ASC, and cleaved caspase 1 (p10), in addition to mitigating oxidative stress by inhibiting the expression of NADPH oxidase 4 (NOX-4) and lowering the levels of reactive oxygen species (ROS) as has been demonstrated in human umbilical vein endothelial cells [66] (refer to Fig